首页 > 最新文献

Klinicka mikrobiologie a infekcni lekarstvi最新文献

英文 中文
[Lethal course of complicated vascular prosthesis infections]. [复杂血管假体感染的致死过程]。
Q3 Medicine Pub Date : 2018-03-01
Ladislav Blahut, Iva Vágnerová, Jana Janečková, Pavel Zbořil, Olga Klementová

Presented are two cases of vascular prosthesis infections complicated by peritonitis with a lethal course. The authors describe complicated antibiotic therapy with findings, exhausted options for surgical therapy and subsequent decision that the condition was untreatable and palliative care was initiated.

本文报告两例血管假体感染并发腹膜炎,病程致命。作者描述了复杂的抗生素治疗和发现,用尽手术治疗的选择,随后决定病情无法治疗,并开始姑息治疗。
{"title":"[Lethal course of complicated vascular prosthesis infections].","authors":"Ladislav Blahut,&nbsp;Iva Vágnerová,&nbsp;Jana Janečková,&nbsp;Pavel Zbořil,&nbsp;Olga Klementová","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Presented are two cases of vascular prosthesis infections complicated by peritonitis with a lethal course. The authors describe complicated antibiotic therapy with findings, exhausted options for surgical therapy and subsequent decision that the condition was untreatable and palliative care was initiated.</p>","PeriodicalId":17909,"journal":{"name":"Klinicka mikrobiologie a infekcni lekarstvi","volume":"24 1","pages":"14-16"},"PeriodicalIF":0.0,"publicationDate":"2018-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36319295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Diagnosis, treatment and prophylaxis of malaria in the Czech Republic]. [捷克共和国疟疾的诊断、治疗和预防]。
Q3 Medicine Pub Date : 2018-03-01
František Stejskal, Eva Nohýnková, Pavel Kosina, Jana Kulichová

Malaria represents the most important parasitic infection imported from the tropics causing death in 1-2 % of travelers with this diagnosis. Around 30 cases of malaria are diagnosed in the Czech Republic every year. Fever is the most common clinical presentation. The most severe forms of malaria are caused by Plasmodium falciparum. The diagnosis of malaria is based on examination of stained thick and thin blood smears. This method enables determination of Plasmodium species and parasite count. The treatment of ma-laria has to be initiated immediately after the laboratory confirmation. In the Czech Republic, uncomplicated falciparum malaria is treated by oral administration of artemether/lumefantrine or atovaquone/proguanil. Complicated falciparum malaria is treated by parenteral administration of quinine in combination with clindamycin. For the chemoprophylaxis of malaria in travelers to the highly endemic regions, atovaquone/proguanil, doxycycline or mefloquine are recommended.

疟疾是从热带输入的最重要的寄生虫感染,在诊断为疟疾的旅行者中造成1- 2%的死亡。捷克共和国每年诊断出大约30例疟疾病例。发烧是最常见的临床表现。最严重的疟疾是由恶性疟原虫引起的。疟疾的诊断是根据染色的厚血涂片和薄血涂片进行检查。该方法可用于疟原虫种类和寄生虫数量的测定。疟疾的治疗必须在实验室确认后立即开始。在捷克共和国,治疗无并发症恶性疟疾的方法是口服蒿甲醚/氨苯曲明或阿托伐醌/普罗胍。复杂的恶性疟疾是由注射奎宁联合克林霉素治疗。对于前往高流行地区的旅行者的疟疾化学预防,建议使用阿托伐醌/普罗胍、强力霉素或甲氟喹。
{"title":"[Diagnosis, treatment and prophylaxis of malaria in the Czech Republic].","authors":"František Stejskal,&nbsp;Eva Nohýnková,&nbsp;Pavel Kosina,&nbsp;Jana Kulichová","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Malaria represents the most important parasitic infection imported from the tropics causing death in 1-2 % of travelers with this diagnosis. Around 30 cases of malaria are diagnosed in the Czech Republic every year. Fever is the most common clinical presentation. The most severe forms of malaria are caused by Plasmodium falciparum. The diagnosis of malaria is based on examination of stained thick and thin blood smears. This method enables determination of Plasmodium species and parasite count. The treatment of ma-laria has to be initiated immediately after the laboratory confirmation. In the Czech Republic, uncomplicated falciparum malaria is treated by oral administration of artemether/lumefantrine or atovaquone/proguanil. Complicated falciparum malaria is treated by parenteral administration of quinine in combination with clindamycin. For the chemoprophylaxis of malaria in travelers to the highly endemic regions, atovaquone/proguanil, doxycycline or mefloquine are recommended.</p>","PeriodicalId":17909,"journal":{"name":"Klinicka mikrobiologie a infekcni lekarstvi","volume":"24 1","pages":"20-30"},"PeriodicalIF":0.0,"publicationDate":"2018-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36319297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Diagnosis and therapy of hepatitis B virus infection: Czech national guidelines]. 乙型肝炎病毒感染的诊断和治疗:捷克国家指南。
Q3 Medicine Pub Date : 2017-12-01
Petr Husa, Jan Šperl, Petr Urbánek, Soňa Fraňková, Stanislav Plíšek, Petr Kümpel, Luděk RoŽnovský

The new recommendations reflect the increase in knowledge that has been reported since the release of previous Czech guidelines in September 2014. The basis for these guidelines were the European Association for the Study of the Liver guidelines from April 2017. According to qualified estimates, there are 240 million people with chronic hepatitis B (HBV) infection worldwide. The Czech Republic is among the countries with a low prevalence of HBV infection. According to the latest seroprevalence study, 0.56 % of the Czech citizens were chronically infected with HBV in 2001. A similar study conducted in only two regions of the Czech Republic in 2013 showed a prevalence of only 0.064 %. HBV infection can lead to serious life-threatening liver damage - fulminant hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC). The main goals of treatment are to prolong the length of life and improve its quality by preventing the progression of chronic hepatitis to cirrhosis, cirrhosis decompensation and development of HCC. The goals may be achieved if HBV replication is suppressed in a sustained manner. Additional goals are prevention of vertical transmission from mother to newborn, inhibition of HBV reactivation and therapy of HBV-related extrahepatic manifestations. Generally, there are two different strategies of chronic hepatitis B therapy available - treatment with nucleoside or nucleotide inhibitors (NIs) or with pegylated interferon alfa. Currently, the vast majority of Czech and European patients are treated with NIs. The NIs that have been approved for HBV treatment in the European Union include lamivudine, adefovir dipivoxil, entecavir (ETV), telbivudin (TBV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF). TAF and TBV have not yet been marketed in the Czech Republic. The main advantages of treatment with potent NIs with a high barrier to resistance (ETV, TDF, TAF) are their predictable high long-term antiviral efficacy leading to undetectable HBV DNA levels in the vast majority of compliant patients as well as their favorable safety profiles. These drugs can be used in any HBV infected patient and represent the only treatment option for patients with decompensated liver cirrhosis, liver transplants, extrahepatic HBV-related manifestations, severe acute hepatitis B or chronic HBV reactivation.

新的建议反映了自2014年9月捷克发布之前的指南以来所报告的知识的增加。这些指南的基础是2017年4月发布的欧洲肝脏研究协会指南。根据合格估计,全世界有2.4亿人感染慢性乙型肝炎(HBV)。捷克共和国是乙肝病毒感染率较低的国家之一。根据最新的血清流行率研究,2001年,0.56%的捷克公民慢性感染乙型肝炎病毒。2013年在捷克共和国的两个地区进行的一项类似研究显示,患病率仅为0.064%。HBV感染可导致严重的危及生命的肝损伤——暴发性肝炎、肝硬化和肝细胞癌(HCC)。治疗的主要目标是通过预防慢性肝炎发展为肝硬化、肝硬化失代偿和HCC的发展来延长生命长度和提高生命质量。如果持续抑制HBV复制,目标可能会实现。其他目标是预防母婴垂直传播,抑制HBV再激活和治疗HBV相关的肝外表现。一般来说,有两种不同的慢性乙型肝炎治疗策略-核苷或核苷酸抑制剂(NIs)或聚乙二醇化干扰素α治疗。目前,绝大多数捷克和欧洲患者接受NIs治疗。在欧盟被批准用于治疗HBV的NIs包括拉米夫定、阿德福韦酯、恩替卡韦(ETV)、替比夫定(TBV)、富马酸替诺福韦二氧吡酯(TDF)和替诺福韦阿拉胺(TAF)。TAF和TBV尚未在捷克共和国销售。使用具有高耐药屏障(ETV, TDF, TAF)的强效NIs治疗的主要优点是其可预测的高长期抗病毒疗效,导致绝大多数依从性患者的HBV DNA水平无法检测,以及其良好的安全性。这些药物可用于任何HBV感染患者,是失代偿肝硬化、肝移植、肝外HBV相关表现、严重急性乙型肝炎或慢性HBV再激活患者的唯一治疗选择。
{"title":"[Diagnosis and therapy of hepatitis B virus infection: Czech national guidelines].","authors":"Petr Husa,&nbsp;Jan Šperl,&nbsp;Petr Urbánek,&nbsp;Soňa Fraňková,&nbsp;Stanislav Plíšek,&nbsp;Petr Kümpel,&nbsp;Luděk RoŽnovský","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The new recommendations reflect the increase in knowledge that has been reported since the release of previous Czech guidelines in September 2014. The basis for these guidelines were the European Association for the Study of the Liver guidelines from April 2017. According to qualified estimates, there are 240 million people with chronic hepatitis B (HBV) infection worldwide. The Czech Republic is among the countries with a low prevalence of HBV infection. According to the latest seroprevalence study, 0.56 % of the Czech citizens were chronically infected with HBV in 2001. A similar study conducted in only two regions of the Czech Republic in 2013 showed a prevalence of only 0.064 %. HBV infection can lead to serious life-threatening liver damage - fulminant hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC). The main goals of treatment are to prolong the length of life and improve its quality by preventing the progression of chronic hepatitis to cirrhosis, cirrhosis decompensation and development of HCC. The goals may be achieved if HBV replication is suppressed in a sustained manner. Additional goals are prevention of vertical transmission from mother to newborn, inhibition of HBV reactivation and therapy of HBV-related extrahepatic manifestations. Generally, there are two different strategies of chronic hepatitis B therapy available - treatment with nucleoside or nucleotide inhibitors (NIs) or with pegylated interferon alfa. Currently, the vast majority of Czech and European patients are treated with NIs. The NIs that have been approved for HBV treatment in the European Union include lamivudine, adefovir dipivoxil, entecavir (ETV), telbivudin (TBV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF). TAF and TBV have not yet been marketed in the Czech Republic. The main advantages of treatment with potent NIs with a high barrier to resistance (ETV, TDF, TAF) are their predictable high long-term antiviral efficacy leading to undetectable HBV DNA levels in the vast majority of compliant patients as well as their favorable safety profiles. These drugs can be used in any HBV infected patient and represent the only treatment option for patients with decompensated liver cirrhosis, liver transplants, extrahepatic HBV-related manifestations, severe acute hepatitis B or chronic HBV reactivation.</p>","PeriodicalId":17909,"journal":{"name":"Klinicka mikrobiologie a infekcni lekarstvi","volume":"23 4","pages":"148-164"},"PeriodicalIF":0.0,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35773878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Antimicrobial activity of ceftolozane/tazobactam against Enterobacteriaceae and Pseudomonas aeruginosa in the Czech Republic in 2016]. [2016年捷克共和国头孢氧唑烷/他唑巴坦对肠杆菌科和铜绿假单胞菌的抗菌活性分析]。
Q3 Medicine Pub Date : 2017-12-01
Helena Žemličková, Vladislav Jakubů, Marta Fridrichová

Objective: Ceftolozane/tazobactam is an antibiotic effective against Gram-negative bacteria(including Pseudomonas aeruginosa).The study aimed at determining the effectiveness of the novel antibiotic in the Czech Republic.

Material and methods: The effectiveness of the antibiotic was studied in 16 Czech laboratories in 822 Enterobacteriaceae isolates (including AmpC and ESBL producers) and P. aeruginosa causing complicated intraabdominal or urinary tract infections. Minimum inhibitory concentrations were determined using the Etest. With the exception of Citrobacter freundii and Enterobacter cloacae, ceftozolane/tazobactam proved to be very effective against Enterobacteriaceae; no P. aeruginosa strain was resistant to the antibiotic.

Conclusion: The results confirmed good activity of ceftozolane/tazobactam in vitro against Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis) and P. aeruginosa in the Czech Republic.

目的:头孢唑烷/他唑巴坦是一种对革兰氏阴性菌(包括铜绿假单胞菌)有效的抗生素。这项研究旨在确定这种新型抗生素在捷克共和国的有效性。材料与方法:在捷克16个实验室对822株肠杆菌科分离株(包括AmpC和ESBL产生株)和铜绿假单胞菌(P. aeruginosa)引起的复杂腹内或尿路感染进行抗生素有效性研究。最低抑菌浓度用Etest测定。除弗氏柠檬酸杆菌和阴沟肠杆菌外,头孢唑啉/他唑巴坦对肠杆菌科细菌非常有效;铜绿假单胞菌无耐药菌株。结论:头孢唑啉/他唑巴坦对捷克产肠杆菌科(大肠杆菌、肺炎克雷伯菌、氧化克雷伯菌、神奇变形杆菌)和铜绿假单胞菌具有良好的体外抑菌活性。
{"title":"[Antimicrobial activity of ceftolozane/tazobactam against Enterobacteriaceae and Pseudomonas aeruginosa in the Czech Republic in 2016].","authors":"Helena Žemličková,&nbsp;Vladislav Jakubů,&nbsp;Marta Fridrichová","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Ceftolozane/tazobactam is an antibiotic effective against Gram-negative bacteria(including Pseudomonas aeruginosa).The study aimed at determining the effectiveness of the novel antibiotic in the Czech Republic.</p><p><strong>Material and methods: </strong>The effectiveness of the antibiotic was studied in 16 Czech laboratories in 822 Enterobacteriaceae isolates (including AmpC and ESBL producers) and P. aeruginosa causing complicated intraabdominal or urinary tract infections. Minimum inhibitory concentrations were determined using the Etest. With the exception of Citrobacter freundii and Enterobacter cloacae, ceftozolane/tazobactam proved to be very effective against Enterobacteriaceae; no P. aeruginosa strain was resistant to the antibiotic.</p><p><strong>Conclusion: </strong>The results confirmed good activity of ceftozolane/tazobactam in vitro against Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis) and P. aeruginosa in the Czech Republic.</p>","PeriodicalId":17909,"journal":{"name":"Klinicka mikrobiologie a infekcni lekarstvi","volume":"23 4","pages":"132-135"},"PeriodicalIF":0.0,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35773875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Concurrent malaria and rickettsiosis in a patient returning from the Republic of South Africa]. [一例从南非共和国返回的患者并发疟疾和立克次体病]。
Q3 Medicine Pub Date : 2017-12-01
Věra Pellantová, Pavel Kosina, Petr Prášil, Hana Zelená, Zuzana Čermáková, Stanislav Plíšek

Definitive diagnosis and therapy proved challenging in the case of a 60-year-old male with malaria and rickettsiosis. Returning travellers who are unwell can present practical difficulties in diagnosis and treatment and the focus here is on conditions relevant to the Republic of South Africa. Malaria, rickettsiosis and Q fever are discussed.

在一名患有疟疾和立克次体病的60岁男性病例中,明确的诊断和治疗证明具有挑战性。身体不适的返回旅行者可能在诊断和治疗方面造成实际困难,这里的重点是与南非共和国有关的情况。讨论了疟疾、立克次体病和Q热。
{"title":"[Concurrent malaria and rickettsiosis in a patient returning from the Republic of South Africa].","authors":"Věra Pellantová,&nbsp;Pavel Kosina,&nbsp;Petr Prášil,&nbsp;Hana Zelená,&nbsp;Zuzana Čermáková,&nbsp;Stanislav Plíšek","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Definitive diagnosis and therapy proved challenging in the case of a 60-year-old male with malaria and rickettsiosis. Returning travellers who are unwell can present practical difficulties in diagnosis and treatment and the focus here is on conditions relevant to the Republic of South Africa. Malaria, rickettsiosis and Q fever are discussed.</p>","PeriodicalId":17909,"journal":{"name":"Klinicka mikrobiologie a infekcni lekarstvi","volume":"23 4","pages":"142-147"},"PeriodicalIF":0.0,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35773877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[First experience with elbasvir/grazoprevir fixed-dose combination in real-life practice in the Czech Republic]. [在捷克共和国的实际实践中首次使用elbasvir/grazoprevir固定剂量联合用药的经验]。
Q3 Medicine Pub Date : 2017-12-01
Petr Husa, Libuše Husová

Hepatitis C virus infection (HCV) is one of the leading causes of chronic liver disease worldwide. The new fixed-dose combination of the highly potent second wave first generation NS5A inhibitor elbasvir (50 mg) and the second generation protease inhibitor grazoprevir (100 mg) is contained in the drug Zepatier. This combination is indicated for the treatment of patients chronically infected with HCV genotypes 1 or 4. Between June and August 2017, the treatment was initiated in 22 patients with chronic viral hepatitis C, with 17 patients being treated in the Department of Infectious Diseases University Hospital Brno and five patients in the Center of Cardiovascular and Transplant Surgery in Brno. All patients were infected with HCV subtype 1b. In all cases, the duration of Zepatier monotherapy (without simultaneous ribavirin administration) was 12 weeks. At the moment, only preliminary results are available. All 22 patients achieved end-of-treatment virologic response. In nine patients, it was already possible to evaluate the virologic response at four weeks after the end of treatment, with sustained virological response (SVR12) was observed in all these patients. The most common complaints were fatigue (3 patients, 14 %) and headache (2.9 %). These problems were not serious and did not interfere with normal daily activities of treated persons.

丙型肝炎病毒感染(HCV)是全球慢性肝病的主要原因之一。高效第二波第一代NS5A抑制剂elbasvir (50mg)和第二代蛋白酶抑制剂grazoprevir (100mg)的新固定剂量组合包含在药物Zepatier中。这种组合适用于慢性感染HCV基因型1或4的患者。在2017年6月至8月期间,22名慢性病毒性丙型肝炎患者开始接受治疗,其中17名患者在布尔诺大学医院传染病科接受治疗,5名患者在布尔诺心血管和移植手术中心接受治疗。所有患者均感染HCV亚型1b。在所有病例中,Zepatier单药治疗(不同时给予利巴韦林)的持续时间为12周。目前,只有初步结果。所有22例患者均达到治疗末期病毒学应答。在9例患者中,已经可以在治疗结束后4周评估病毒学反应,在所有这些患者中观察到持续病毒学反应(SVR12)。最常见的主诉是疲劳(3例,14%)和头痛(2.9%)。这些问题并不严重,也不妨碍患者的正常日常活动。
{"title":"[First experience with elbasvir/grazoprevir fixed-dose combination in real-life practice in the Czech Republic].","authors":"Petr Husa,&nbsp;Libuše Husová","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hepatitis C virus infection (HCV) is one of the leading causes of chronic liver disease worldwide. The new fixed-dose combination of the highly potent second wave first generation NS5A inhibitor elbasvir (50 mg) and the second generation protease inhibitor grazoprevir (100 mg) is contained in the drug Zepatier. This combination is indicated for the treatment of patients chronically infected with HCV genotypes 1 or 4. Between June and August 2017, the treatment was initiated in 22 patients with chronic viral hepatitis C, with 17 patients being treated in the Department of Infectious Diseases University Hospital Brno and five patients in the Center of Cardiovascular and Transplant Surgery in Brno. All patients were infected with HCV subtype 1b. In all cases, the duration of Zepatier monotherapy (without simultaneous ribavirin administration) was 12 weeks. At the moment, only preliminary results are available. All 22 patients achieved end-of-treatment virologic response. In nine patients, it was already possible to evaluate the virologic response at four weeks after the end of treatment, with sustained virological response (SVR12) was observed in all these patients. The most common complaints were fatigue (3 patients, 14 %) and headache (2.9 %). These problems were not serious and did not interfere with normal daily activities of treated persons.</p>","PeriodicalId":17909,"journal":{"name":"Klinicka mikrobiologie a infekcni lekarstvi","volume":"23 4","pages":"137-141"},"PeriodicalIF":0.0,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35773876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Diagnosis and therapy of hepatitis B virus infection: Czech national guidelines]. 乙型肝炎病毒感染的诊断和治疗:捷克国家指南。
Q3 Medicine Pub Date : 2017-10-30 DOI: 10.14735/AMGH2017419
P. Husa, J. Sperl, P. Urbánek, S. Fraňková, S. Plíšek, P. Kümpel, L. Rožnovský
The new recommendations reflect the increase in knowledge that has been reported since the release of previous Czech guidelines in September 2014. The basis for these guidelines were the European Association for the Study of the Liver guidelines from April 2017. According to qualified estimates, there are 240 million people with chronic hepatitis B (HBV) infection worldwide. The Czech Republic is among the countries with a low prevalence of HBV infection. According to the latest seroprevalence study, 0.56 % of the Czech citizens were chronically infected with HBV in 2001. A similar study conducted in only two regions of the Czech Republic in 2013 showed a prevalence of only 0.064 %. HBV infection can lead to serious life-threatening liver damage - fulminant hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC). The main goals of treatment are to prolong the length of life and improve its quality by preventing the progression of chronic hepatitis to cirrhosis, cirrhosis decompensation and development of HCC. The goals may be achieved if HBV replication is suppressed in a sustained manner. Additional goals are prevention of vertical transmission from mother to newborn, inhibition of HBV reactivation and therapy of HBV-related extrahepatic manifestations. Generally, there are two different strategies of chronic hepatitis B therapy available - treatment with nucleoside or nucleotide inhibitors (NIs) or with pegylated interferon alfa. Currently, the vast majority of Czech and European patients are treated with NIs. The NIs that have been approved for HBV treatment in the European Union include lamivudine, adefovir dipivoxil, entecavir (ETV), telbivudin (TBV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF). TAF and TBV have not yet been marketed in the Czech Republic. The main advantages of treatment with potent NIs with a high barrier to resistance (ETV, TDF, TAF) are their predictable high long-term antiviral efficacy leading to undetectable HBV DNA levels in the vast majority of compliant patients as well as their favorable safety profiles. These drugs can be used in any HBV infected patient and represent the only treatment option for patients with decompensated liver cirrhosis, liver transplants, extrahepatic HBV-related manifestations, severe acute hepatitis B or chronic HBV reactivation.
新的建议反映了自2014年9月捷克发布以前的指导方针以来所报告的知识的增加。这些指南的依据是2017年4月欧洲肝脏研究协会的指南。根据有资格的估计,全世界有2.4亿人感染慢性乙型肝炎。捷克共和国是HBV感染率较低的国家之一。根据最新的血清流行率研究,2001年,0.56%的捷克公民长期感染HBV。2013年仅在捷克共和国的两个地区进行的一项类似研究显示,患病率仅为0.064%。HBV感染可导致严重的危及生命的肝损伤——暴发性肝炎、肝硬化和肝细胞癌(HCC)。治疗的主要目标是通过预防慢性肝炎进展为肝硬化、肝硬化失代偿和HCC的发展来延长寿命并提高其质量。如果以持续的方式抑制HBV复制,这些目标可能会实现。其他目标是预防从母亲到新生儿的垂直传播,抑制HBV再激活和治疗HBV相关的肝外表现。一般来说,有两种不同的慢性乙型肝炎治疗策略可用——核苷或核苷酸抑制剂(NIs)治疗或聚乙二醇干扰素α治疗。目前,绝大多数捷克和欧洲患者接受NIs治疗。欧盟已批准用于HBV治疗的NIs包括拉米夫定、阿德福韦酯、恩替卡韦(ETV)、替比夫定(TBV)、富马酸替诺福韦二酯(TDF)和替诺福韦阿拉芬酰胺(TAF)。TAF和TBV尚未在捷克共和国上市。具有高耐药性屏障的强效NIs(ETV、TDF、TAF)治疗的主要优点是其可预测的长期抗病毒疗效高,导致绝大多数顺从患者的HBV DNA水平无法检测,以及其良好的安全性。这些药物可用于任何HBV感染患者,是失代偿性肝硬化、肝移植、肝外HBV相关表现、严重急性乙型肝炎或慢性HBV再激活患者的唯一治疗选择。
{"title":"[Diagnosis and therapy of hepatitis B virus infection: Czech national guidelines].","authors":"P. Husa, J. Sperl, P. Urbánek, S. Fraňková, S. Plíšek, P. Kümpel, L. Rožnovský","doi":"10.14735/AMGH2017419","DOIUrl":"https://doi.org/10.14735/AMGH2017419","url":null,"abstract":"The new recommendations reflect the increase in knowledge that has been reported since the release of previous Czech guidelines in September 2014. The basis for these guidelines were the European Association for the Study of the Liver guidelines from April 2017. According to qualified estimates, there are 240 million people with chronic hepatitis B (HBV) infection worldwide. The Czech Republic is among the countries with a low prevalence of HBV infection. According to the latest seroprevalence study, 0.56 % of the Czech citizens were chronically infected with HBV in 2001. A similar study conducted in only two regions of the Czech Republic in 2013 showed a prevalence of only 0.064 %. HBV infection can lead to serious life-threatening liver damage - fulminant hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC). The main goals of treatment are to prolong the length of life and improve its quality by preventing the progression of chronic hepatitis to cirrhosis, cirrhosis decompensation and development of HCC. The goals may be achieved if HBV replication is suppressed in a sustained manner. Additional goals are prevention of vertical transmission from mother to newborn, inhibition of HBV reactivation and therapy of HBV-related extrahepatic manifestations. Generally, there are two different strategies of chronic hepatitis B therapy available - treatment with nucleoside or nucleotide inhibitors (NIs) or with pegylated interferon alfa. Currently, the vast majority of Czech and European patients are treated with NIs. The NIs that have been approved for HBV treatment in the European Union include lamivudine, adefovir dipivoxil, entecavir (ETV), telbivudin (TBV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF). TAF and TBV have not yet been marketed in the Czech Republic. The main advantages of treatment with potent NIs with a high barrier to resistance (ETV, TDF, TAF) are their predictable high long-term antiviral efficacy leading to undetectable HBV DNA levels in the vast majority of compliant patients as well as their favorable safety profiles. These drugs can be used in any HBV infected patient and represent the only treatment option for patients with decompensated liver cirrhosis, liver transplants, extrahepatic HBV-related manifestations, severe acute hepatitis B or chronic HBV reactivation.","PeriodicalId":17909,"journal":{"name":"Klinicka mikrobiologie a infekcni lekarstvi","volume":"23 4 1","pages":"148-164"},"PeriodicalIF":0.0,"publicationDate":"2017-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47067894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
[Guideline for the diagnosis and treatment of acute bacterial meningitis]. 【急性细菌性脑膜炎诊断与治疗指南】。
Q3 Medicine Pub Date : 2017-06-01
Olga DŽupová, Miroslav Helcl, Renata Kračmarová, Lenka Krbková, Radana Pařízková, Luděk RoŽnovský

Acute bacterial meningitis is a severe infectious disease of the central nervous system. Its incidence decreases but lethality and sequelae remain high. The early initiation of appropriate treatment is a factor strongly determining the patient´s prognosis. The authors submit the Czech national guideline for diagnosis and treatment of community-acquired acute bacterial meningitis which has to provide clear and simple recommendations for clinicans involved in the care of meningitis in adults and children. The national guideline was based on the European guideline published in 2016 and adapted for the situation in the Czech Republic. It was acknowledged (approved? ratified?) by the Society for Epidemiology and Microbiology and the Society for Medical Microbiology of the Czech Medical Association.

急性细菌性脑膜炎是一种严重的中枢神经系统传染病。其发病率下降,但致死率和后遗症仍然很高。早期开始适当的治疗是决定患者预后的一个重要因素。作者提交了捷克国家社区获得性急性细菌性脑膜炎诊断和治疗指南,该指南必须为参与成人和儿童脑膜炎护理的临床医生提供明确和简单的建议。国家指南以2016年发布的欧洲指南为基础,并根据捷克共和国的情况进行了调整。它被承认(批准)了?由流行病学和微生物学学会和捷克医学会医学微生物学学会批准?)。
{"title":"[Guideline for the diagnosis and treatment of acute bacterial meningitis].","authors":"Olga DŽupová,&nbsp;Miroslav Helcl,&nbsp;Renata Kračmarová,&nbsp;Lenka Krbková,&nbsp;Radana Pařízková,&nbsp;Luděk RoŽnovský","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Acute bacterial meningitis is a severe infectious disease of the central nervous system. Its incidence decreases but lethality and sequelae remain high. The early initiation of appropriate treatment is a factor strongly determining the patient´s prognosis. The authors submit the Czech national guideline for diagnosis and treatment of community-acquired acute bacterial meningitis which has to provide clear and simple recommendations for clinicans involved in the care of meningitis in adults and children. The national guideline was based on the European guideline published in 2016 and adapted for the situation in the Czech Republic. It was acknowledged (approved? ratified?) by the Society for Epidemiology and Microbiology and the Society for Medical Microbiology of the Czech Medical Association.</p>","PeriodicalId":17909,"journal":{"name":"Klinicka mikrobiologie a infekcni lekarstvi","volume":"23 2","pages":"76-84"},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35400699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Salmonellosis in an infant as a result of indirect contact with reptiles]. [婴儿因间接接触爬行动物而感染沙门氏菌病]。
Q3 Medicine Pub Date : 2017-06-01
Zuzana Tomaštíková, Martina Mrázková, Marie Kaňáková, Renáta Karpíšková

Reported is a case of enteritis caused by Salmonella Oranienburg in an approximately one-month-old infant due to indirect contact with reptiles. An epidemiological investigation included tests of faeces of bearded dragons (Pogona vitticeps) kept in the patient's household that revealed Salmonella Oranienburg. The comparison of Salmonella isolates obtained from the infant's stools and the reptiles' faeces using macrorestriction analysis showed 100% similarity, confirming that the reptiles were the source of the infection. The transfer of Salmonella was probably indirect through the other family members. The detection of rare Salmonella serotypes should -lead to inclusion of less common sources of infection such as reptiles into epidemiological investigations.

报告一例由奥兰氏沙门氏菌引起的肠炎,发生在一名大约一个月大的婴儿身上,原因是间接接触爬行动物。一项流行病学调查包括对患者家中保存的胡须龙(Pogona vitticeps)的粪便进行测试,结果发现了奥兰尼堡沙门氏菌。从婴儿粪便中分离出的沙门氏菌与爬行动物粪便中分离出的沙门氏菌进行宏观限制分析,结果相似度为100%,证实爬行动物是感染源。沙门氏菌可能是通过其他家庭成员间接传播的。对罕见沙门氏菌血清型的检测应导致将不太常见的感染源(如爬行动物)纳入流行病学调查。
{"title":"[Salmonellosis in an infant as a result of indirect contact with reptiles].","authors":"Zuzana Tomaštíková,&nbsp;Martina Mrázková,&nbsp;Marie Kaňáková,&nbsp;Renáta Karpíšková","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Reported is a case of enteritis caused by Salmonella Oranienburg in an approximately one-month-old infant due to indirect contact with reptiles. An epidemiological investigation included tests of faeces of bearded dragons (Pogona vitticeps) kept in the patient's household that revealed Salmonella Oranienburg. The comparison of Salmonella isolates obtained from the infant's stools and the reptiles' faeces using macrorestriction analysis showed 100% similarity, confirming that the reptiles were the source of the infection. The transfer of Salmonella was probably indirect through the other family members. The detection of rare Salmonella serotypes should -lead to inclusion of less common sources of infection such as reptiles into epidemiological investigations.</p>","PeriodicalId":17909,"journal":{"name":"Klinicka mikrobiologie a infekcni lekarstvi","volume":"23 2","pages":"61-63"},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35507446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A rare mechanism of resistance to colistin in Escherichia coli isolated from raw poultry meat]. [从生禽肉中分离出的大肠杆菌对粘菌素的罕见耐药性机制]。
Q3 Medicine Pub Date : 2017-06-01
Renáta Karpíšková, Ivana Koláčková, Tereza Gelbíčová, Marie Zobaníková

Plasmid-mediated resistance to colistin is a recently described phenomenon. The study reports this new type of colistin resistance in food isolates of Escherichia coli in the Czech Republic. Strains with phenotypically determined colistin resistance were studied for presence of the mcr-1 and mcr-2 genes. A positive finding of E. coli harboring the mcr-1 gene was confirmed in a sample of raw minced turkey meat imported from Poland. Two different strains of E. coli carrying the mcr-1 gene were detected in the same sample. This is the first reported case of this type of resistance in E. coli strains isolated from foods at retail in the Czech Republic.

质粒介导的粘菌素耐药性是最近发现的一种现象。该研究报告了捷克共和国大肠杆菌食物分离株中这种新型粘菌素耐药性。研究了表型确定的耐粘菌素菌株是否存在mcr-1和mcr-2基因。在从波兰进口的生绞火鸡肉样本中证实发现含有mcr-1基因的大肠杆菌呈阳性。在同一样品中检测到两种不同的携带mcr-1基因的大肠杆菌菌株。这是从捷克共和国零售食品中分离出的大肠杆菌菌株中首次报告的这类耐药病例。
{"title":"[A rare mechanism of resistance to colistin in Escherichia coli isolated from raw poultry meat].","authors":"Renáta Karpíšková,&nbsp;Ivana Koláčková,&nbsp;Tereza Gelbíčová,&nbsp;Marie Zobaníková","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Plasmid-mediated resistance to colistin is a recently described phenomenon. The study reports this new type of colistin resistance in food isolates of Escherichia coli in the Czech Republic. Strains with phenotypically determined colistin resistance were studied for presence of the mcr-1 and mcr-2 genes. A positive finding of E. coli harboring the mcr-1 gene was confirmed in a sample of raw minced turkey meat imported from Poland. Two different strains of E. coli carrying the mcr-1 gene were detected in the same sample. This is the first reported case of this type of resistance in E. coli strains isolated from foods at retail in the Czech Republic.</p>","PeriodicalId":17909,"journal":{"name":"Klinicka mikrobiologie a infekcni lekarstvi","volume":"23 2","pages":"58-60"},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35507445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Klinicka mikrobiologie a infekcni lekarstvi
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1